Mylan wins restraining order against Apotex for generic version of GSK's Paxil

theflyonthewall.com

Mylan (MYL) announced that the U.S. District Court for the District of New Jersey granted its motion for a temporary restraining order against Apotex Inc. and Apotex Corporation in litigation relating to Paroxetine CR, the authorized generic of GlaxoSmithKline's (GSK) Paxil CR. The District Court ordered Apotex to immediately discontinue all sales and supply of Paroxetine CR. Mylan previously obtained an order enjoining GlaxoSmithKline from supplying Paroxetine CR to Apotex. Mylan has an exclusive license to an Orange Book patent pertaining to Paxil CR which expires in July 2016.

View Comments (0)